[사회]5 vaccines soon to be vaccinated…when are they introduced and what are their pros and cons?

[앵커]

Corona 19 vaccine will be introduced in Korea sequentially from the end of this month.

Preventive effects and storage methods are different for each type of vaccine, and the timing of vaccination is different depending on the amount of secured.

Reporter Son Hyo-jeong summarized the advantages and disadvantages of the five vaccines and when they were introduced.

[기자]

There are five types of Corona 19 vaccines to be introduced in Korea.

They are Pfizer, developed jointly by AstraZeneca of the UK and the US and Germany, and Modena, Janssen and Novabacks of the US.

First of all, AstraZeneca, which will be suitable for the majority of the first quarter vaccination targets, can be stored at room temperature of 2-8 degrees Celsius, so it can be inoculated at a local hospital.

However, as the average preventive effect was somewhat low at 62%, and safety controversy arose due to lack of clinical data, some countries recommended not to vaccinate the elderly aged 65 or older.

The Ministry of Food and Drug Safety plans to decide on final approval sooner or later based on the opinion of the vaccine verification advisory group that it is safe for the elderly to inoculate.

[김상봉 / 식약처 바이오생약국장 : 만 65세 이상을 포함한 전체 대상자에서 예방 효과가 확인된 점 등을 종합적으로 고려할 때 참여대상자 중 고령자 수가 적다는 이유만으로 고령자에 대한 투여를 배제할 수 없다는 의견이었습니다.]

Pfizer and Modena’s preventive effects are high at 95% and 94.1%, respectively, but difficult storage methods are a challenge.

Since Pfizer should be stored at -70 degrees Celsius and Modena -20 degrees Celsius to prevent deterioration, the government is planning to establish 250 separate vaccination centers nationwide.

NovaVax is made with a synthetic antigen method similar to that of conventional flu vaccines and has been evaluated relatively well for safety.

The prevention effect is also high at 89.3%, but it was found to be less effective against mutant viruses originating in South Africa.

On the other hand, the vaccine of Janssen, a subsidiary of the Johnson & Johnson pharmaceutical division of the United States, has a 66% preventive effect, but it was found to be effective in preventing severe diseases.

In addition, it can be stored at room temperature, and unlike other Corona 19 vaccines, it is said that it only needs to be inoculated once.

The Pfizer vaccine will be introduced in Korea first in the middle of this month, with an initial volume of 60,000 people.

Next, 10 million AstraZeneca people will be introduced in the first quarter, 20 million people will be introduced in the second quarter, and 10 million Pfizer will be introduced in the third quarter.

When the phase 3 clinical trials for Janssen’s 6 million people are over, the timing of its introduction will be confirmed, and NovaVax is undergoing final negotiations to introduce 20 million people.

YTN Son Hyojeong[[email protected]]is.

※’Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]